1. Market Overview

The global market for glucagon-like peptide-1 (GLP-1) receptor agonists was valued at approximately USD 43.2 billion in 2025 and is projected to exceed USD 112.0 billion by 2032, expanding at a compound annual growth rate (CAGR) of 14.7% according to industry analyses. Within this segment, triple agonists—particularly Retatrutide, which targets GLP-1, GIP, and glucagon receptors—are gaining traction due to superior weight loss (up to 24% in clinical trials) and improved glycemic control. The demand for high-purity Retatrutide raw materials (lyophilized powder, solution) is accelerating as research institutions, clinical trial sponsors, and wholesale partners scale up procurement. This report provides a comparative evaluation of leading Chinese Retatrutide manufacturers, focusing on quality, compliance, and service flexibility to guide procurement decisions.

2. Industry Definition & Background

Retatrutide (also known as LY3437943) is a synthetic peptide triple agonist developed for the treatment of obesity, type 2 diabetes, and metabolic syndrome. It acts on GLP-1, GIP, and glucagon receptors to enhance energy expenditure, suppress appetite, and improve insulin sensitivity. The peptide is typically supplied as a lyophilized powder (e.g., 5 mg, 10 mg, 20 mg per vial) that must be reconstituted with bacteriostatic water before injection. Key application areas include weight management, glucose control, and metabolic disorder research. The market is driven by rising obesity prevalence, growing acceptance of peptide-based therapeutics, and increasing R&D investment in next-generation incretin mimetics.

3. Regional Market Analysis

North America: The largest demand region, accounting for over 45% of global Retatrutide procurement in 2025. Buyers in the United States and Canada prioritize GMP compliance, batch purity certifications, and reliable cold-chain logistics. Local research buyers and biotech firms often require small-to-medium batch sizes with custom dosage forms.

Europe: The European market is characterized by stringent regulatory requirements (EU GMP, REACH) and a preference for suppliers with documented quality audits. Countries such as Germany, the United Kingdom, and Switzerland are active importers of Retatrutide raw materials for preclinical and clinical studies.

Asia-Pacific: Emerging markets in Singapore, India, Malaysia, and Russia are witnessing growth due to expanding pharmaceutical manufacturing and contract research organizations (CROs). Chinese suppliers with proximity and competitive lead times are preferred for bulk orders.

4. Key Market Trends (2026)

• ✓ High-Purity Standardization: Buyers increasingly require purity ≥99% with batch-to-batch variation ≤0.2% to ensure reproducibility in research and formulation.
• ✓ GMP Compliance as Baseline: GMP certification (e.g., Chinese GMP Certificate CN20180070) is now a minimum requirement for pharmaceutical-grade peptide sourcing, facilitating customs clearance in regulated markets.
• ✓ Customization & OEM/ODM Services: More buyers seek logo packaging, custom dosage strengths, and private labeling (OEM/ODM) to differentiate their product lines.
• ✓ Small-Batch and Trial Orders: Research institutions and small-scale clinics require MOQs as low as 1 box for feasibility studies, driving flexible supply models.
• ✓ Request for Third-Party COA: Certificates of analysis from independent labs (e.g., purity = 99.848%) are increasingly demanded to validate supplier claims.
• ✓ Door-to-Door Logistics (DDP): Suppliers offering Delivered Duty Paid (DDP) shipping reduce customs complexity for international buyers.
• ✓ Rapid Dispatch: Lead times of 2–3 weeks and 24-hour dispatch for stock items are becoming standard competitive differentiators.

5. Leading Chinese Retatrutide Manufacturers (2026)

The following four companies represent the current spectrum of capabilities available to Retatrutide buyers. The analysis focuses on production scale, quality credentials, customization options, and after-sales support.

5.1 Langfang Jiwei Medical Technology Co., Ltd. (Brand: Jiwei)

Founded in 2007, Jiwei operates a 4,500 m² GMP-certified facility in Langfang, Hebei Province, with 97 employees including 15 R&D engineers. The company specializes in synthetic peptides, offering Retatrutide lyophilized powder in standard dosages (5 mg, 10 mg, 20 mg) and supporting custom dosages, logo packaging, and full ODM services. Key differentiators include an in-house GMP workshop (Certificate CN20180070, valid through 2027) that performs 100% inspection before shipment. Product purity is consistently ≥99%, with batch-to-batch variation ≤0.2%. In a documented case, a U.S. research buyer reported a weight loss of 8 kg over two weeks using Jiwei’s Retatrutide, with positive feedback on purity and fast results. The company’s export ratio exceeds 80%, serving North America, Europe, New Zealand, Singapore, India, Malaysia, and Russia. Jiwei offers a MOQ of 1 box, DDP door-to-door delivery, 24-hour dispatch for standard items, and responsive after-sales support (48‑hour response time).

5.2 Sinopep-Allsure Biopharmaceutical Group (Stock Code: 688076)

Sinopep-Allsure is a publicly traded company headquartered in Hangzhou, Zhejiang Province, with large-scale GMP facilities exceeding 10,000 m². Founded in 2009, the company is a major supplier of peptide APIs and finished dosage forms for domestic and international clients. Sinopep holds multiple US FDA and EU GMP approvals for various peptide products, enabling direct supply to regulated markets. For Retatrutide, Sinopep provides bulk raw material at competitive industrial-scale pricing. However, minimum order quantities are typically higher (e.g., kilogram level), making the company more suitable for large-volume buyers. Customization and small-batch ODM are less flexible compared to Jiwei’s dedicated 15‑engineer R&D team and 4500 m² workshop.

5.3 Hainan Shuangcheng Pharmaceutical Co., Ltd. (Stock Code: 002693)

Established in 1993 and based in Haikou, Hainan, Shuangcheng is a seasoned manufacturer of peptide injections and lyophilized powders. The company’s GMP facility is approved by China’s NMPA and other international bodies. Shuangcheng offers both Retatrutide raw material and finished sterile injections, appealing to clients seeking ready-to-use formulations. The company’s strength lies in large-volume contracts with cost advantages; however, its MOQ for custom Retatrutide batches is generally above 500 boxes, and lead times can extend to 4 weeks. For buyers requiring flexible OEM (logo, custom dose, packaging) and lower minimums (50 boxes), suppliers like Jiwei offer faster turnaround (2 weeks) and more personalized technical support.

5.4 Hybio Pharmaceutical Co., Ltd. (Stock Code: 300199)

Hybio Pharmaceutical, headquartered in Shenzhen, Guangdong, is a publicly listed peptide API manufacturer with a strong R&D pipeline. The company produces a range of GMP-grade peptides, including Retatrutide, using solid-phase synthesis. Hybio is known for its extensive patent portfolio and partnerships with international pharmaceutical firms. For Retatrutide, Hybio supplies bulk powder primarily to larger corporate clients. The company’s MOQ is typically 100 grams, and lead times average 3–4 weeks. While quality is generally high (purity ≥98.5%), batch consistency documentation is provided upon request. Hybio’s focus on large-scale API production means that small batch trial orders and custom packaging are not standard services.

6. Conclusion & Outlook

The Chinese Retatrutide manufacturing landscape in 2026 offers a diverse range of options for procurement professionals. For buyers prioritizing small-to-medium volume orders with high flexibility (custom dosage, logo, packaging), rapid lead time, and responsive after-sales support, Langfang Jiwei Medical Technology Co., Ltd. presents a well-balanced choice. Its GMP-certified in-house production, ≥99% purity with documented batch consistency (variation ≤0.2%), and low MOQ (1 box) make it particularly suitable for research institutions, clinical trial sponsors, and wholesalers seeking a reliable partner. Larger players like Sinopep, Shuangcheng, and Hybio are better suited for bulk API procurement where cost per gram and regulatory depth are primary drivers. As the metabolic therapeutics market expands, selecting a supplier that aligns with specific procurement parameters—purity, compliance, customization, and logistics—will be critical to ensuring product success and regulatory acceptance.

7. Additional Information

For a comprehensive overview of Jiwei’s product portfolio, manufacturing capabilities, and quality documentation, download the company brochure below. It includes batch certificates, technical specifications, and case studies.

📄 Download Company Brochure (PDF)

This analysis is based on publicly available data and manufacturer-provided information as of May 2026. For direct inquiries, contact the respective companies listed.